Haoyang Cheng

Haoyang Cheng

Auto-generated profile, based on publicly available information

Haoyang Cheng

RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
BLBin Liu
Bin Liu
XDXiaolong Dong
Xiaolong Dong
HCHaoyang Cheng
Haoyang Cheng
CZChunwei Zheng
Chunwei Zheng
ZCZexiang Chen
Zexiang Chen
ESErik J. Sontheimer
Erik J. Sontheimer

14 September 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
BLBin Liu
Bin Liu
XDXiaolong Dong
Xiaolong Dong
CZChunwei Zheng
Chunwei Zheng
DKDavid Keener
David Keener
ZCZexiang Chen
Zexiang Chen
ESErik J. Sontheimer
Erik J. Sontheimer

1 June 2022 in GEN Biotechnology
Verified
Journal Article
Closed access
HZHan Zhang
Han Zhang
NBNathan Bamidele
Nathan Bamidele
PLPengpeng Liu
Pengpeng Liu
OOOgooluwa Ojelabi
Ogooluwa Ojelabi
XGXin D. Gao
Xin D. Gao
ESErik J. Sontheimer
Erik J. Sontheimer
Base editors (BEs) have opened new avenues for the treatment of genetic diseases. However, advances in delivery approaches are needed to enable disease targeting of a broad range of tissues and cell types. Adeno-associated virus (AAV) vectors remain one of the most promising delivery vehicles for gene therapies. Currently, most BE/guide combinations and their promoters exceed the packaging limit (∼5 kb) of AAVs. Dual-AAV delivery strategies often require high viral doses that impose safety concerns. In this study, we engineered an adenine base editor (ABE) using a compact Cas9 from Neisseria meningitidis (Nme2Cas9). Compared with the well-characterized Streptococcus pyogenes Cas9-containing ABEs, ABEs using Nme2Cas9 (Nme2-ABE) possess a distinct protospacer adjacent motif (N 4 CC) and editing window, exhibit fewer off-target effects, and can efficiently install therapeutically relevant mutations in both human and mouse genomes. Importantly, we show that in vivo delivery of Nme2-ABE and its guide RNA by a single AAV vector can efficiently edit mouse genomic loci and revert the disease mutation and phenotype in an adult mouse model of tyrosinemia. We anticipate that Nme2-ABE, by virtue of its compact size and broad targeting range, will enable a range of therapeutic applications with improved safety and efficacy due in part to packaging in a single-vector system.

1 December 2023 in GEN Biotechnology
Verified
Journal Article
Closed access
ZCZexiang Chen
Zexiang Chen
KKKaren Kelly
Karen Kelly
HCHaoyang Cheng
Haoyang Cheng
XDXiaolong Dong
Xiaolong Dong
AHAdam K. Hedger
Adam K. Hedger
JWJonathan K. Watts
Jonathan K. Watts
Prime editing (PE) has gained significant attention as a next-generation gene editing technology, owing to its unique advantages. However, realizing its potential in vivo requires effective delivery strategies. While adeno-associated virus (AAV) has been employed for in vivo delivery of prime editors in research settings, it presents inherent limitations related to vector size, ongoing expression, and inability to re-dose patients. Conversely, lipid nanoparticles (LNPs) do not face these limitations and are emerging as a leading nonviral approach for the delivery of gene editors. In this study, we demonstrate successful co-delivery of chemically modified pegRNA and prime editor mRNA using LNPs for in vivo PE. We investigate the impact of pegRNA chemical modifications on editing efficiency and explore different re-dosing regimens. In a daily-repeat dose regimen, we saw striking liver toxicity and no increase in editing; by contrast, weekly repeat dosing was well tolerated and enabled 1.8-fold increase in editing efficacy. Furthermore, in the NOD scid gamma immunodeficient mouse model, the efficacy of LNP-delivered PE was enhanced by 2.8-fold. In addition, the nature of the ionizable lipids and phospholipids strongly influenced PE efficiency in vivo . Overall, these findings will greatly contribute to the future development of LNPs as a robust platform for delivering prime editors in vivo , fostering progress in PE research and therapeutic applications.

29 April 2026 in Nature
Verified
Journal Article
Closed access
BLBin Liu
Bin Liu
APAndrew Petti
Andrew Petti
XZXuntao Zhou
Xuntao Zhou
HCHaoyang Cheng
Haoyang Cheng
JGJenny Gao
Jenny Gao
WXWen Xue
Wen Xue

13 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
HZHan Zhang
Han Zhang
NBNathan Bamidele
Nathan Bamidele
PLPengpeng Liu
Pengpeng Liu
OOOgooluwa Ojelabi
Ogooluwa Ojelabi
XGXin D. Gao
Xin D. Gao
ESErik J. Sontheimer
Erik J. Sontheimer
Base editors (BEs) have opened new avenues for the treatment of genetic diseases. However, advances in delivery approaches are needed to enable disease targeting of a broad range of tissues and cell types. Adeno-associated virus (AAV) vectors remain one of the most promising delivery vehicles for gene therapies. Currently, most BE/guide combinations and their promoters exceed the packaging limit (~5 kb) of AAVs. Dual-AAV delivery strategies often require high viral doses that impose safety concerns. In this study, we engineered an adenine base editor using a compact Cas9 from Neisseria meningitidis (Nme2Cas9). Compared to the well-characterized Streptococcus pyogenes Cas9-containing ABEs, Nme2-ABE possesses a distinct PAM (N 4 CC) and editing window, exhibits fewer off-target effects, and can efficiently install therapeutically relevant mutations in both human and mouse genomes. Importantly, we show that in vivo delivery of Nme2-ABE and its guide RNA by a single-AAV vector can efficiently edit mouse genomic loci and revert the disease mutation and phenotype in an adult mouse model of tyrosinemia. We anticipate that Nme2-ABE, by virtue of its compact size and broad targeting range, will enable a range of therapeutic applications with improved safety and efficacy due in part to packaging in a single-vector system.